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Introduction
Cluster headache is a rare but disabling neurological disor-
der, characterised, according to the International Classifica-
tion of Headache Disorders-3 (ICHD-3), by unilateral severe 
headache with associated autonomic features and agitation. 
Despite proven abortive and preventive treatments, many 
cases remain refractory, leading to adverse psychosocial and 
employment outcomes. Understanding the efficacy of cur-
rent and emerging therapies may help to improve clinical 
management of such cases.
This month’s journal club reviews three papers relating to 
treatment of cluster headache. The first explores the effec-
tiveness and adverse effects of a range of acute treatments 
for cluster headache, based on a large international sam-
ple. The second is a pooled analysis of two previous trials 
evaluating non-invasive vagus nerve stimulation (nVNS) 
as an acute treatment for cluster headache. The third paper 
describes a double-blind, randomised, placebo-controlled 
study assessing the monoclonal antibody galcanezumab as 
a preventive agent for cluster headache.
Effectiveness of oxygen and other acute 
treatments for cluster headache: results 
from the cluster headache questionnaire, 
an international survey
Data was collected over a two-year period via the Cluster 
Headache Questionnaire which was available as an inter-
net-based, self-administered survey in several countries. 
The majority of respondents were from the United States, 
United Kingdom and Canada. The questionnaire was adver-
tised on headache society websites and via email to society 
members. The questionnaire comprised 152 items within 8 
sub-sections including consent and personal details. A fur-
ther section also addressed the ICHD-3 criteria for diagnosis 
of cluster headache and enabled exclusion of those without 
this diagnosis. The remaining sections addressed effective-
ness of medication, physical and psychological complica-
tions of treatments, mood scores and difficulties obtaining 
medication.
A range of statistical tests analysed and compared the 
effectiveness of acute treatments in participants with diagno-
ses of definite or probable cluster headache and in respond-
ents over the age of 65.
A total of 2193 participants met criteria for the study 
(1604 cluster headache and 589 probable cluster headache). 
Fifty-four per cent of all respondents reported complete or 
very effective response to oxygen and triptans, with lower 
efficacy for other acute treatments: dihydroergotamine (25%), 
ergotamine (17%), intranasal ketamine (14%), caffeine and 
energy drinks (17%), opioids (6%), intranasal capsaicin 
(5%), intranasal lidocaine (2%). Adverse effects in the form 
of physical or emotional complications were lowest for oxy-
gen, lidocaine and ketamine, but higher for ergot derivatives, 
opioids and triptans. Responses in the over 65 age group for 
treatment efficacy and adverse effect profile were similar to 
the combined cohort. Patients with episodic cluster head-
ache responded better to oxygen than those with chronic clus-
ter headache, although there was no difference in response 
between episodic and chronic cluster headache to triptans.
Further analysis revealed difficulty obtaining oxygen as 
compared to other treatments, with reasons cited including 
practicalities, the respondent’s smoking status and issues 
relating to insurance cover.
Comment: This large international sample demonstrates the 
high efficacy and minimal complication rate of oxygen as an 
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acute treatment for cluster headache, with similar efficacy 
for triptans but with a higher adverse effect profile. The poor 
efficacy and high side effect profile of opioid treatments is 
also noted. Strengths of this study include the large sample 
number and the strict inclusion of ICHD-3 criteria. Limita-
tions include the lack of validation of the questionnaire prior 
to the study. Self-administration introduces subjectivity and 
recall bias, with no verification from the respondents’ medi-
cal notes or practitioner. The questionnaire also did not allow 
respondents to elaborate on the nature of adverse effects. 
Finally, the questionnaire did not include indomethacin or 
steroids as acute treatments despite their wide use in auto-
nomic cephalalgias.
Pearson  et al. Headache 2019 Feb;59(2):235–249
Differential efficacy of non‑invasive vagus 
nerve stimulation for the acute treatment 
of episodic and chronic cluster headache: 
a meta‑analysis
This study is a meta-analysis of two randomised, double-
blind, sham controlled trials (ACT1, ACT2) which evalu-
ated nVNS as an acute treatment in episodic and chronic 
cluster headache. The similarity between the study designs 
and populations of the two trials allowed pooling of data and 
enabled greater statistical power in the analysis of results.
225 participants with episodic (n = 112) and chronic ( n 
= 113) cluster headaches were included from both data sets. 
The main outcome measures were the primary endpoints of 
each study. Logistic regression models were used to analyse 
the proportion of participants whose first treated attack had 
improved from pain intensity 2–4 to 0–1 at 15 min after 
treatment initiation, and the proportion of participants in 
whom ≥ 50% of all treated attacks had improved from pain 
intensity 2–4 to 0–1 at 15 min after treatment initiation.
The study demonstrated that, among participants with 
episodic cluster headache, more participants treated with 
nVNS that with sham achieved a statistically significant 
improvement in their pain intensity in the first treated attack 
(ACT1 group p < 0.01, ACT2 group p   = 0.07, pooled p < 
0.01) and a higher proportion of pain improvement in all 
treated attacks (ACT1 p < 0.05, ACT2 p < 0.05, pooled p  < 
0.01). Thirty-eight of 124 participants in the nVNS group 
experienced adverse effects, the most common of which was 
perioral muscle contraction. Efficacy was not demonstrated 
for nVNS for chronic cluster headache.
Comment: This paper shows that nVNS is an effective acute 
treatment for episodic cluster headache (p < 0.01) with no 
serious short-term safety concerns. Strengths of this study 
include the pooling of data from two similar trials to reach 
significant conclusions. However, there were differences 
between the two studies, such as variation in stimulation 
sites, and the allowance of extra pulses in ACT2, which may 
have accounted for the slight differences in efficacy between 
the two trials. Possible explanations for the poor response 
of chronic cluster headache patients to nVNS include higher 
levels of inter-paroxysmal pain in chronic headache, and dif-
ferences in brain pharmacology between chronic and epi-
sodic cluster headache.
De Coo et al. Cephalalgia 2019. Vol 39(8) 967–977
Trial of galcanezumab in prevention 
of episodic cluster headache
Cluster headache disease activity is associated with altera-
tions in calcitonin gene–related peptide (CGRP) levels, 
hence the rationale for evaluation of galcanezumab (a 
humanized monoclonal antibody to CGRP) for the preven-
tion of cluster headache. One hundred and six participants 
were enrolled over a 3-year period at 35 sites in Europe 
and North America. Despite the wide geographical, the 
planned sample size of 162 was not reached because too 
few patients met eligibility criteria during the recruitment 
period. The trial comprised a screening period, a prospec-
tive baseline period, and an 8-week double-blind placebo-
controlled period. Patients transitioned from the screening 
period to the prospective baseline period once they had 
entered an active cluster headache phase. The prospective 
baseline period involved monitoring of headache attacks 
over 10–15 days and was used to verify a diagnosis of epi-
sodic cluster headache. Patients who met all eligibility cri-
teria were randomly assigned to galcanezumab (300 mg) 
or placebo once monthly in a double-blind manner. The 
number and severity of attacks was then monitored over an 
eight-week period via an electronic patient diary. Patients 
were further observed over a four-month wash-out period 
to monitor for side effects.
The mean reduction in the weekly frequency of cluster 
headache attacks was 8.7 attacks in the galcanezumab group, 
as compared to 5.2 in the placebo group (p = 0.04). The per-
centage of patients who had a reduction of at least 50% in 
headache frequency at week 3 was 71% in the galcanezumab 
group and 53% in the placebo group. There was no substan-
tial difference in the incidence of adverse effects between 
the groups.
Comment: This study demonstrates that subcutaneous gal-
canezumab reduced the frequency of attacks of episodic 
cluster headache as compared with placebo. After week 4 of 
the double-blind assessment period, the frequency of head-
ache attacks between the two groups converged which could 
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reflect the natural remission phase of the cluster headache 
episode. Limitations of this study include small sample size, 
and the inclusion of patients with episodic but not chronic 
cluster headache. Finally, it would be interesting to compare 
the doses used in this paper for the treatment of cluster head-
ache with those used in the prevention of migraine.
Goadsby et al. N Eng J Med 2019; 381:132–41
Conclusion
The first paper highlights the efficacy and safety of oxy-
gen as a first line, rapidly acting treatment for cluster head-
ache, with reasonable efficacy and side effect profiles for 
several other agents. The second and third papers dem-
onstrate encouraging progress with neuromodulatory and 
monoclonal antibody treatments for episodic cluster head-
ache although it remains unclear why many treatments are 
ineffective in chronic cluster headache. Further work on the 
pathophysiological differences between episodic and chronic 
cluster headache could help tailor therapies for chronic clus-
ter headache.
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